Advanced search
Publication Cover
International Journal of Hyperthermia Volume 40, 2023 - Issue 1
Submit an article Journal homepage
1,698
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Thermal ablation versus radiotherapy for inoperable stage III non-small cell lung cancer: a propensity score matching analysis

Wei-Yu Yanga Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China;b Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, ChinaORCID Iconhttps://orcid.org/0000-0002-6315-8660View further author information
ORCID Icon,
Yu Hea Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China;b Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, ChinaView further author information
,
Muyun Penga Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China;b Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, ChinaView further author information
,
Zhe Zhanga Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China;b Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, ChinaView further author information
,
Shouzhi Xiea Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China;b Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, ChinaView further author information
,
Zeyu Wua Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China;b Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, ChinaView further author information
,
Qikang Hua Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China;b Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, ChinaCorrespondence[email protected]
View further author information
&
Fenglei Yua Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China;b Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2154577 | Received 04 Oct 2022, Accepted 29 Nov 2022, Published online: 19 Dec 2022

Figures & data

Figure 1. Kaplan–Meier survival curves for OS (A) and CSS (B) in inoperable patients with stage III NSCLC. OS: overall survival; CSS: cancer-specific survival; NSCLC: non-small cell lung cancer.

Figure 1. Kaplan–Meier survival curves for OS (A) and CSS (B) in inoperable patients with stage III NSCLC. OS: overall survival; CSS: cancer-specific survival; NSCLC: non-small cell lung cancer.

Table 1. Characteristics of patients with stage III NSCLC before and after PSM, n (%).

Table 2. Univariable and multivariable analyses of OS and CSS in stage III NSCLC patients receiving radiotherapy or thermal ablation before PSM, n (%).

Figure 2. Kaplan–Meier survival curves for OS (A) and CSS (B) in inoperable patients with stage III NSCLC after PSM. OS: overall survival; CSS: cancer-specific survival; NSCLC: non-small cell lung cancer; PSM: propensity score matching.

Figure 2. Kaplan–Meier survival curves for OS (A) and CSS (B) in inoperable patients with stage III NSCLC after PSM. OS: overall survival; CSS: cancer-specific survival; NSCLC: non-small cell lung cancer; PSM: propensity score matching.

Figure 3. Kaplan–Meier survival curves for OS between the thermal ablation and radiotherapy groups when age was <65 years (A), 65–74 years (B), 75–84 years (C), or ≥85 years (D) before PSM. OS: overall survival; PSM: propensity score matching.

Figure 3. Kaplan–Meier survival curves for OS between the thermal ablation and radiotherapy groups when age was <65 years (A), 65–74 years (B), 75–84 years (C), or ≥85 years (D) before PSM. OS: overall survival; PSM: propensity score matching.

Figure 4. Kaplan–Meier survival curves for OS between the thermal ablation and radiotherapy groups when age was <65 years (A), 65–74 years (B), 75–84 years (C), or ≥85 years (D) after PSM. OS: overall survival; PSM: propensity score matching.

Figure 4. Kaplan–Meier survival curves for OS between the thermal ablation and radiotherapy groups when age was <65 years (A), 65–74 years (B), 75–84 years (C), or ≥85 years (D) after PSM. OS: overall survival; PSM: propensity score matching.

Figure 5. Kaplan–Meier survival curves between the thermal ablation and radiotherapy groups when TNM substage was IIIA (A, B) or IIIB (C, D) before PSM. PSM: propensity score matching.

Figure 5. Kaplan–Meier survival curves between the thermal ablation and radiotherapy groups when TNM substage was IIIA (A, B) or IIIB (C, D) before PSM. PSM: propensity score matching.

Figure 6. Forest plot depicting subgroup analysis of OS between the TA and radiotherapy groups after PSM. NOS: not otherwise specified; SCC: squamous cell carcinoma; ADC: adenocarcinoma; LCC: large cell carcinoma; Inf: infinity; OS: overall survival; TA: thermal ablation; PSM: propensity score matching.

Figure 6. Forest plot depicting subgroup analysis of OS between the TA and radiotherapy groups after PSM. NOS: not otherwise specified; SCC: squamous cell carcinoma; ADC: adenocarcinoma; LCC: large cell carcinoma; Inf: infinity; OS: overall survival; TA: thermal ablation; PSM: propensity score matching.
Supplemental material

Supplemental Material

Download PDF (1,004.2 KB)

Data availability statement

Publicly available datasets were analyzed in this study. The data can be found here: https://seer.cancer.gov/.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.